On October 27, 2026, Altimmune drew $10.0 million in principal under Tranche Three of its $125.0 million Loan and Security Agreement with Hercules Capital. The draw was triggered by the achievement of specific clinical and financial milestones. Consequently, the amortization date and interest-only period have been extended to June 1, 2028, and the company must maintain qualified cash equal to at least 60% of the outstanding term loan principal. A 1.0% Tranche Facility Charge was deducted from the funding proceeds. Altimmune operates in the biopharmaceutical industry, focusing on the development of treatments for infectious diseases and cancer.
